Transwell assays were utilized to assess the migratory and invasive CRC cells in the CCAT2‐KO, GNB2‐OE, and CCAT2‐KO+GNB2‐OE treatment groups. This evidence concerns the gene CCAT2 and colorectal carcinoma.